AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:58Neutral
Price Target:
$69.00
▲(2.21% Upside)
Action:ReiteratedDate:04/21/26
The score reflects a strong technical uptrend and a meaningful 2025 financial rebound (positive operating/free cash flow and sharply reduced losses), tempered by still-negative profitability/negative gross profit and weak valuation support (negative P/E). The spin-off and royalty-focused strategy are positive but carry execution and transition risk.
Positive Factors
Royalty-focused business model
The spin-off leaves AnaptysBio as a royalty/asset manager holding Jemperli and imsidolimab royalty streams. A royalty model is structurally lower capital intensity than R&D, producing more predictable, long-duration cash flows and reducing future financing needs if royalties are stable.
Negative Factors
Negative gross profit
Persistent negative gross profit signals that core product or service economics have not covered direct costs historically. Even with royalties, negative gross margin trends increase earnings-quality risk and imply structural cost issues that can limit sustainable profitability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Royalty-focused business model
The spin-off leaves AnaptysBio as a royalty/asset manager holding Jemperli and imsidolimab royalty streams. A royalty model is structurally lower capital intensity than R&D, producing more predictable, long-duration cash flows and reducing future financing needs if royalties are stable.
Read all positive factors
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.94B
Dividend YieldN/A
Average Volume (3M)627.22K
Price to Earnings (P/E)4.5
Beta (1Y)0.81
Revenue Growth157.01%
EPS Growth94.31%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,100,903
10 Day Avg. Volume537,791
30 Day Avg. Volume627,217
Financial Highlights & Ratios
PEG Ratio0.75
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue13.05
Enterprise Value/Gross Profit13.19
Enterprise Value/Ebitda45.87
Forecast
1Y Price Target
$78.27Price Target Upside15.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.69
Revenue Forecast (FY)$105.03M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 recepto...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (its programs are largely in clinical development). Under these types of deals, revenue is typically generated from (1) upfront payments re...
AnaptysBio Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 50.32M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | |||||
| Total Assets | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | |||||
| Free Cash Flow | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Positive
67.51
Price Trends
59.68
Positive
52.92
Positive
40.04
Positive
Market Momentum
2.50
Negative
58.87
Neutral
60.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 67.51 is above the 20-day moving average (MA) of 63.56, above the 50-day MA of 59.68, and above the 200-day MA of 40.04, indicating a bullish trend. The MACD of 2.50 indicates Negative momentum. The RSI at 58.87 is Neutral, neither overbought nor oversold. The STOCH value of 60.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 42 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $6.11B | -39.12 | -20.02% | ― | ― | 8.38% | |
58 Neutral | $1.94B | 4.53 | 1813.84% | ― | 157.01% | 94.31% | |
57 Neutral | $227.36M | 8.71 | 14.25% | ― | 6774.96% | ― | |
52 Neutral | $870.96M | -5.60 | 4438.87% | ― | 144.57% | 32.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.25B | -13.39 | -42.90% | ― | ― | 13.36% | |
46 Neutral | $352.97M | -12.74 | -43.61% | ― | -100.00% | -20.71% |
* Healthcare Sector Average
ANAB
AnaptysBio
69.78
55.96
405.03%
MGTX
Meiragtx Holdings
9.70
3.25
50.39%
KROS
Keros Therapeutics
11.71
-2.85
-19.57%
CMPX
Compass Therapeutics
1.94
0.08
4.30%
OLMA
Olema Pharmaceuticals
14.63
9.07
163.13%
TERN
Terns Pharmaceuticals
52.95
49.65
1504.55%
AnaptysBio Corporate Events
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
Positive
Apr 20, 2026
On April 20, 2026, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, separating its biotechnology RD operations from a royalty-focused business that will retain and manage Jemperli and imsidolimab royalty streams and related colla...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
Positive
Mar 27, 2026
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.